This Market Spotlight report covers the Sarcoma market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, patent information, probability of success, recent events and analyst opinion, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

• Datamonitor Healthcare estimates that in 2017, there were approximately 413,300 incident cases of sarcoma worldwide, and forecasts that number to increase to 485,100 incident cases by 2026.
• Worldwide, the majority of sarcoma cases were soft tissue and other extraosseous sarcomas (83%), while a smaller proportion were osteosarcomas and other malignant bone tumors (17%).
• The approved drugs in the sarcoma space focus on targets such as tumor necrosis factor-alpha, microtubules, platelet-derived growth factor receptor, KIT/c-KIT, vascular endothelial growth factor receptor, and DNA. All of the approved drugs are administered via the intravenous route, except for Votrient, which is an oral drug.
• The majority of industry-sponsored drugs in active clinical development for sarcoma are in Phase II. Therapies in development for sarcoma focus on a wide variety of targets. The majority of these therapies are administered via the oral and intravenous routes, with the remainder being intraocular, subretinal, subconjunctival, intradermal, intratumoral, and topical formulations.
• • High-impact upcoming events in the sarcoma space comprise topline Phase III trial results for TRC105. The overall likelihood of approval of a Phase I sarcoma asset is 13.6%, and the average probability a drug advances from Phase III is 62.5%. Drugs, on average, take 9.4 years from Phase I to approval, compared to 9.2 years in the overall oncology space.
• There have been 18 licensing and asset acquisition deals involving sarcoma drugs during 2013–18. The licensing agreement between Adaptimmune and GlaxoSmithKline in 2014 for $1,150m, to develop and commercialize NY-ESO-1(C259), was the largest deal during the period.
• The clinical trials distribution across Phase I–IV indicates that the vast majority of trials for sarcoma have been in the early and mid-phases of development, with 90% of trials in Phase I–II, and only 10% in Phase III–IV.
• The US has a substantial lead in the number of sarcoma clinical trials globally. France leads the major EU markets, while Israel has the top spot in Asia.
• Clinical trial activity in the sarcoma space is dominated by completed trials. Novartis has the highest number of completed clinical trials for sarcoma, with 15 trials.
• Merck & Co leads industry sponsors with the highest number of overall clinical trials for sarcoma, followed by Novartis and Pfizer.